

**F. No. ND/MA/20/000166**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**New Drugs Division**

FDA Bhawan, Kotla Road,  
New Delhi-110002

Dated:

To

M/s. MSN Laboratories Private Limited.,  
MSN House: Plot No: C-24, Industrial Estate,  
Sanathnagar, Hyderabad -500018, Telangana.

08 JUN 2021

**Subject:** "Permission to conduct Clinical Trial entitled "A Randomized, Double blind, Placebo controlled Multi-centric, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Aciptadil for Injection 500 mcg/vial in Treatment of Subjects Hospitalized with Respiratory Failure/Acute Respiratory Distress Syndrome associated with severe Coronavirus Disease (COVID-19)" regarding.

Sir,

With reference to your application No. ND/CT21/FF/2020/23041 dated 07.12.2020 please find enclosed herewith the permission in Form CT-06, No. CT/ND/65/2021 to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019, granted based on evaluation in consultation with Subject Expert Committee (SEC) as part of accelerated approval process in light of COVID-19 outbreak.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,



(Dr. V. G. Somani)  
Central Licensing Authority

**Conditions of Permission**

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) CMC data as per the requirement like characterization details, certificate of analysis, stability data etc. should be submitted to the CDSCO before initiation of the clinical trials.**
- (xx) Undertaking of all the Investigator as per Table 4 of the New Drugs & Clinical Trial, 2019 of all the proposed clinical trial sites should be submitted to CDSCO before the initiation of the trial.**
- (xxi) The firm should submit 20 patient's data in each arm, evaluated for atleast 28 days with proper methodology for further consideration.**



**FORM CT-06**

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

Number of the permission: CT/ND/65/2021

Dated: 08 JUN 2021

The Central Licensing Authority hereby permits **M/s. MSN Laboratories Private Limited., MSN House: Plot No: C-24, Industrial Estate, Sanathnagar, Hyderabad-500018, Telangana, India** to conduct clinical trial of the new drug as per protocol No. AVIP/MSN/P3/2021, V 1.2 dated 11 MAY 2021 in the below mentioned clinical trial sites.

## 2. Details of new drug or investigational new drug:

|                                         |                                                                                                                                                                                                 |                                                                                                                                |              |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------|
| <b>Names of the new drug</b>            | Aviptadil for Injection 500 mcg/Vial                                                                                                                                                            |                                                                                                                                |              |
| <b>Therapeutic class:</b>               | Vasoactive Instestinal Polypeptide.                                                                                                                                                             |                                                                                                                                |              |
| <b>Dosage form:</b>                     | Lyophilized injection                                                                                                                                                                           |                                                                                                                                |              |
| <b>Composition:</b>                     | Label Claim: Aviptadil 500 mcg per Vial<br>Each ml Contains Aviptadil ---100mcg                                                                                                                 |                                                                                                                                |              |
| <b>Indications:</b>                     | Indicated for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.                                                                                  |                                                                                                                                |              |
|                                         |                                                                                                                                                                                                 |                                                                                                                                |              |
| <b>Details of clinical trial sites-</b> |                                                                                                                                                                                                 |                                                                                                                                |              |
| <b>Sr. No.</b>                          | <b>Name of Principal Investigator &amp; Trial sites</b>                                                                                                                                         | <b>Ethics Committee Registration Number</b>                                                                                    | <b>Name/</b> |
| 1.                                      | Dr. Dnyaneshwar Macctiindra Halnor<br>Vijay vallabh Hospital and Medical Research centre, ptot Nagar, Phase No-428, Tirupati 1, Bolinj, Virar(West), Maharastra                                 | Institutional Ethics Committee<br>Vijay Vallabh Hospital and Medical Research Centre.<br><br><b>ECR/880/Inst/MH/2017/RR-20</b> |              |
| 2                                       | Dr Jignesh N. Shah<br>Bharati Hospital and Research Centre, Bharati Vidyapeeth Deemed to be University, 2nd Floor, Department of Critical Care medicine, Medical College, Katraj, Pune- 411043. | Institutional Ethics Committee, Aayush Hospital.<br><br><b>ECR/313/Inst/MH/2013/RR-19</b>                                      |              |
| 3                                       | Dr. R S Raman<br>Maharaja Agrasen Hospital, Near Metro Station Jain Muni Guru Ramkrishan Marg Block C, Shivaji Park, West Punjabi Bagh, Delhi, 110026.                                          | Institutional Ethics Committee ,Maharaja Agrasen Hospital<br><br><b>ECR/745/Inst/DI/2015/RR-18</b>                             |              |
| 4                                       | Dr Marri Hari Krishna<br>Ayush NRI LEPL Health Care Private Limited 48-13-3 3A Ring Road Opp.Siddhartha Medical College, Sri Ramachandra Nagar, Vijayawada, Andhra Pradesh 520008.              | Institutional Ethics Committee, Aayush Hospital<br><br><b>EC No :ECR/550/Inst/AP/2014/RR-17</b>                                |              |

|   |                                                                                            |                                                                                               |
|---|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| 5 | Dr. Keyur Brahme<br>SSG Hospital, Medical College –<br>Baroda, Gujarat.                    | Institutional Ethics Committee for<br>Human Research.<br><br><b>ECR/85/Inst/GJ/2013/RR-19</b> |
| 6 | Dr Chirag Rathod<br>GMERS Medical College & Hospital,<br>Gotri, Vadodara- 390021, Gujarat. | Institutional Human Ethics<br>Committee.<br><br><b>ECR/28/Inst/GJ/2013/RR-16</b>              |

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940

Place .....

Date .....

08 JUN 2021

(Dr. V. G. Somani)  
Central Licensing Authority  
Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health and Family Welfare  
FDA Bhawan, Kotla Road, I.T.O.  
New Delhi-110002